UA76695C2 - Химера il6ril6 для лікування нейродегенеративних захворювань - Google Patents
Химера il6ril6 для лікування нейродегенеративних захворювань Download PDFInfo
- Publication number
- UA76695C2 UA76695C2 UA2002010458A UA2002010458A UA76695C2 UA 76695 C2 UA76695 C2 UA 76695C2 UA 2002010458 A UA2002010458 A UA 2002010458A UA 2002010458 A UA2002010458 A UA 2002010458A UA 76695 C2 UA76695 C2 UA 76695C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cells
- chimera
- apa
- cultures
- neurons
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 title claims description 9
- 210000003169 central nervous system Anatomy 0.000 claims description 20
- 208000016192 Demyelinating disease Diseases 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 210000005036 nerve Anatomy 0.000 claims description 14
- 229940126601 medicinal product Drugs 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 230000007850 degeneration Effects 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 230000000472 traumatic effect Effects 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 abstract description 13
- 208000025966 Neurological disease Diseases 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 112
- 210000004116 schwann cell Anatomy 0.000 description 48
- 210000002569 neuron Anatomy 0.000 description 46
- 210000004248 oligodendroglia Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 35
- 108010083674 Myelin Proteins Proteins 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 210000003050 axon Anatomy 0.000 description 25
- 230000004069 differentiation Effects 0.000 description 24
- 230000023105 myelination Effects 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 22
- 102000006386 Myelin Proteins Human genes 0.000 description 21
- 241000700159 Rattus Species 0.000 description 21
- 101710107068 Myelin basic protein Proteins 0.000 description 19
- 230000006698 induction Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 210000005012 myelin Anatomy 0.000 description 15
- 102000047918 Myelin Basic Human genes 0.000 description 14
- 210000003594 spinal ganglia Anatomy 0.000 description 13
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000000835 fiber Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 210000004498 neuroglial cell Anatomy 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 229930195712 glutamate Natural products 0.000 description 10
- 210000001428 peripheral nervous system Anatomy 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 210000003497 sciatic nerve Anatomy 0.000 description 9
- AYNDKKQQUZPETC-NXVVXOECSA-N (z)-2,3-bis(2,4,5-trimethylthiophen-3-yl)but-2-enedinitrile Chemical compound CC1=C(C)SC(C)=C1\C(C#N)=C(\C#N)C1=C(C)SC(C)=C1C AYNDKKQQUZPETC-NXVVXOECSA-N 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 206010029350 Neurotoxicity Diseases 0.000 description 8
- 206010044221 Toxic encephalopathy Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 231100000228 neurotoxicity Toxicity 0.000 description 8
- 230000007135 neurotoxicity Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000002752 melanocyte Anatomy 0.000 description 7
- 210000000933 neural crest Anatomy 0.000 description 7
- 210000000578 peripheral nerve Anatomy 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 206010012305 Demyelination Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000028389 Nerve injury Diseases 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 230000008764 nerve damage Effects 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004112 neuroprotection Effects 0.000 description 5
- 230000000324 neuroprotective effect Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 210000003007 myelin sheath Anatomy 0.000 description 4
- 210000005044 neurofilament Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000000609 ganglia Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 108700005087 Homeobox Genes Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 206010056677 Nerve degeneration Diseases 0.000 description 2
- 102000014413 Neuregulin Human genes 0.000 description 2
- 108050003475 Neuregulin Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000000782 cerebellar granule cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 210000002856 peripheral neuron Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 101150111743 po gene Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 description 1
- 108091023231 Ap4A Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101100310222 Caenorhabditis briggsae she-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 102100028682 Claudin-11 Human genes 0.000 description 1
- 108050007280 Claudin-11 Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 101100256026 Drosophila melanogaster meigo gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700023863 Gene Components Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000868422 Homo sapiens Sushi, nidogen and EGF-like domain-containing protein 1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000048238 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100035917 Peripheral myelin protein 22 Human genes 0.000 description 1
- 101710199257 Peripheral myelin protein 22 Proteins 0.000 description 1
- 241000030360 Peromyscus truei Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 102100031269 Putative peripheral benzodiazepine receptor-related protein Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000711981 Sais Species 0.000 description 1
- 241000181331 Saron Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 244000025012 Spondias pinnata Species 0.000 description 1
- 235000005658 Spondias pinnata Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100032853 Sushi, nidogen and EGF-like domain-containing protein 1 Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037185 brain physiology Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000004060 excitotoxin Substances 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000012554 master batch record Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008010 parenteral excipient Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
- 229950001870 spizofurone Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- -1 such as the MVR Proteins 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13058699A IL130586A0 (en) | 1999-06-21 | 1999-06-21 | IL6RIL6 chimera for the treatment of demyelinating diseases |
PCT/IL2000/000363 WO2000078331A2 (en) | 1999-06-21 | 2000-06-21 | Il6ril6 chimera for the treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
UA76695C2 true UA76695C2 (uk) | 2006-09-15 |
Family
ID=11072949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2002010458A UA76695C2 (uk) | 1999-06-21 | 2000-06-21 | Химера il6ril6 для лікування нейродегенеративних захворювань |
Country Status (21)
Country | Link |
---|---|
US (1) | US7201896B1 (da) |
EP (1) | EP1185293B1 (da) |
JP (1) | JP4846148B2 (da) |
KR (1) | KR100678290B1 (da) |
CN (1) | CN1164328C (da) |
AT (1) | ATE306280T1 (da) |
AU (1) | AU778662B2 (da) |
BR (1) | BR0011363A (da) |
CA (1) | CA2374997C (da) |
DE (1) | DE60023139T2 (da) |
DK (1) | DK1185293T3 (da) |
EA (1) | EA004626B1 (da) |
EE (1) | EE05559B1 (da) |
ES (1) | ES2250140T3 (da) |
HK (1) | HK1047549A1 (da) |
IL (2) | IL130586A0 (da) |
MX (1) | MXPA02000116A (da) |
NO (1) | NO329028B1 (da) |
UA (1) | UA76695C2 (da) |
WO (1) | WO2000078331A2 (da) |
ZA (1) | ZA200109488B (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1317273T3 (da) | 2000-09-14 | 2006-09-04 | Ares Trading Sa | Anvendelse af IL-6R/IL-6-kimærer mod Huntingtons sygdom |
DE10107737A1 (de) * | 2001-02-16 | 2002-09-05 | S Rose John Christian Albrecht | Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie |
CN100405062C (zh) * | 2001-04-10 | 2008-07-23 | 利兰·斯坦福青年大学托管委员会 | 抗体特异性分布的治疗和诊断使用 |
IL147412A0 (en) * | 2001-12-31 | 2002-08-14 | Yeda Res & Dev | The use of il6r/il6 chimera in nerve cell regeneration |
WO2004111210A1 (en) * | 2003-06-12 | 2004-12-23 | Yeda Research & Development Co.Ltd | Enhancement of oligodendrocyte differentiation |
US20070071727A1 (en) * | 2003-11-14 | 2007-03-29 | Olsson Mats J | Melanocytes in therapy of neurodegenerative diseases |
IL161672A0 (en) * | 2004-04-29 | 2004-09-27 | Yeda Res & Dev | Compositions and methods for therapy of chemotherapy-induced neuropathy |
IL163856A0 (en) * | 2004-09-01 | 2005-12-18 | Applied Research Systems | Use of IL-6 in vascular complications |
JP2019511261A (ja) * | 2016-02-12 | 2019-04-25 | エイエルエス・セラピー・デベロップメント・インスティテュートALS Therapy Development Institute | 運動データに基づいたalsの進行の測定 |
WO2018056412A1 (ja) * | 2016-09-23 | 2018-03-29 | 国立大学法人大阪大学 | シュワン細胞分化促進剤及び末梢神経再生促進剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL122818A0 (en) * | 1997-07-10 | 1998-08-16 | Yeda Res & Dev | Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof |
JPH1148413A (ja) | 1997-08-06 | 1999-02-23 | Dainippon Printing Co Ltd | ホルムアルデヒド捕捉壁紙およびその製造方法 |
JP4859153B2 (ja) * | 1999-02-25 | 2012-01-25 | 東ソー株式会社 | 新規神経系細胞分化促進剤 |
-
1999
- 1999-06-21 IL IL13058699A patent/IL130586A0/xx unknown
-
2000
- 2000-06-21 EE EEP200100689A patent/EE05559B1/xx not_active IP Right Cessation
- 2000-06-21 KR KR1020017015303A patent/KR100678290B1/ko not_active IP Right Cessation
- 2000-06-21 DE DE60023139T patent/DE60023139T2/de not_active Expired - Lifetime
- 2000-06-21 CN CNB008089108A patent/CN1164328C/zh not_active Expired - Fee Related
- 2000-06-21 BR BR0011363-8A patent/BR0011363A/pt not_active Application Discontinuation
- 2000-06-21 AT AT00939022T patent/ATE306280T1/de active
- 2000-06-21 EP EP00939022A patent/EP1185293B1/en not_active Expired - Lifetime
- 2000-06-21 WO PCT/IL2000/000363 patent/WO2000078331A2/en active IP Right Grant
- 2000-06-21 EA EA200200063A patent/EA004626B1/ru not_active IP Right Cessation
- 2000-06-21 DK DK00939022T patent/DK1185293T3/da active
- 2000-06-21 CA CA2374997A patent/CA2374997C/en not_active Expired - Fee Related
- 2000-06-21 JP JP2001504394A patent/JP4846148B2/ja not_active Expired - Fee Related
- 2000-06-21 MX MXPA02000116A patent/MXPA02000116A/es active IP Right Grant
- 2000-06-21 US US09/980,823 patent/US7201896B1/en not_active Expired - Fee Related
- 2000-06-21 AU AU54231/00A patent/AU778662B2/en not_active Ceased
- 2000-06-21 ES ES00939022T patent/ES2250140T3/es not_active Expired - Lifetime
- 2000-06-21 UA UA2002010458A patent/UA76695C2/uk unknown
-
2001
- 2001-11-16 ZA ZA200109488A patent/ZA200109488B/xx unknown
- 2001-11-20 NO NO20015673A patent/NO329028B1/no not_active IP Right Cessation
- 2001-12-19 IL IL147188A patent/IL147188A/en not_active IP Right Cessation
-
2002
- 2002-12-19 HK HK02109201A patent/HK1047549A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA200200063A1 (ru) | 2002-06-27 |
NO20015673D0 (no) | 2001-11-20 |
ATE306280T1 (de) | 2005-10-15 |
MXPA02000116A (es) | 2003-07-21 |
EP1185293B1 (en) | 2005-10-12 |
EE05559B1 (et) | 2012-08-15 |
DE60023139D1 (de) | 2006-02-23 |
DK1185293T3 (da) | 2005-12-27 |
ZA200109488B (en) | 2002-11-18 |
NO329028B1 (no) | 2010-08-02 |
CA2374997C (en) | 2010-04-13 |
HK1047549A1 (en) | 2003-02-28 |
ES2250140T3 (es) | 2006-04-16 |
NO20015673L (no) | 2001-12-17 |
AU5423100A (en) | 2001-01-09 |
KR100678290B1 (ko) | 2007-02-05 |
IL130586A0 (en) | 2000-06-01 |
CA2374997A1 (en) | 2000-12-28 |
CN1164328C (zh) | 2004-09-01 |
BR0011363A (pt) | 2002-02-26 |
EA004626B1 (ru) | 2004-06-24 |
WO2000078331A3 (en) | 2001-07-05 |
JP2003502382A (ja) | 2003-01-21 |
IL147188A (en) | 2015-09-24 |
KR20020013901A (ko) | 2002-02-21 |
US7201896B1 (en) | 2007-04-10 |
JP4846148B2 (ja) | 2011-12-28 |
DE60023139T2 (de) | 2006-05-04 |
CN1364088A (zh) | 2002-08-14 |
AU778662B2 (en) | 2004-12-16 |
EP1185293A2 (en) | 2002-03-13 |
EE200100689A (et) | 2003-02-17 |
WO2000078331A2 (en) | 2000-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Morrissey et al. | Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. | |
Deng et al. | GDNF modifies reactive astrogliosis allowing robust axonal regeneration through Schwann cell-seeded guidance channels after spinal cord injury | |
Kretz et al. | Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation | |
Nesti et al. | Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone | |
Kadi et al. | Differential effects of chemokines on oligodendrocyte precursor proliferation and myelin formation in vitro | |
JP2015529685A (ja) | 筋萎縮性側索硬化症の処置のための組成物および方法 | |
UA76695C2 (uk) | Химера il6ril6 для лікування нейродегенеративних захворювань | |
Zhang et al. | Long distance directional growth of dopaminergic axons along pathways of netrin-1 and GDNF | |
Cao et al. | Involvement of NCAM in the effects of GDNF on the neurite outgrowth in the dopamine neurons | |
WO2019147036A1 (ko) | 뇌유래-신경영양인자를 발현하는 중간엽줄기세포 및 이의 용도 | |
DK2440225T3 (da) | Hidtil ukendte anvendelser af hip/pap eller derivater deraf | |
Gao et al. | Minocycline prevents the inflammatory response after retinal detachment, where microglia phenotypes being regulated through A20 | |
AU2001259453B2 (en) | Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis | |
KR101544398B1 (ko) | FoxA2 및 Nurr1 도입을 이용한 중뇌 도파민성 신경세포로의 분화방법 | |
EP2630965A1 (en) | A polypeptide for the protection from neurodegeneration in patients with amyotrophic lateral sclerosis (ALS) | |
Gu et al. | Expression and regulation of versican in neural precursor cells and their lineages | |
Deng et al. | GDNF reverses the inhibitory properties of reactive astrocytes allowing robust axonal regeneration through Schwann cell-seeded guidance channels after spinal cord injury | |
Nakamoto et al. | Tissues exhibiting inhibiory and repulsive activities during the initial stages of neurite outgrowth from the dorsal root ganglion in the chick embryo | |
US20090324612A1 (en) | Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule | |
WO1996034619A1 (en) | Methods of preventing neuron degeneration and promoting neuron regeneration | |
Wu et al. | Transplantation of Neuregulin1-Overexpressing Bone Marrow Mesenchymal Cells Accelerates Motor Functional Recovery by Facilitating Neurite Outgrowth and Reducing Cell Apoptosis in Rat after Spinal Cord Injury | |
US20090291887A1 (en) | Proteins of the SDF-1-Family for the Manufacturing of a Medicament | |
KR20100136633A (ko) | 개의 베타-신경 성장 인자 및 이를 함유하는 개의 신경손상 관련 질환 치료용 수의학적 조성물 | |
Hunt | Molecular approaches to axonal regeneration | |
Doherty et al. | Molecular specificity of ganglioside action on neurite regeneration in cell cultures of sensory neurons |